All In Biotech

Drug Trial Radar · NCT06364631

CARE1 Pragmatic Clinical Trial

First Line Randomised Study Platform to Optimize Treatment in Patients With Metastatic Renal Cell Carcinoma

Last checked: Nov 20, 2026Latest source record: Jan 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,250 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,250

Planned (sponsor's estimate)

Start

Apr 12, 2024

Primary completion

May 5, 2032

Study completion May 5, 2032

Sponsor

Lead sponsor
Gustave Roussy, Cancer Campus, Grand ParisAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
European Commission; CRIS Cancer Foundation; National Cancer Institute, France; Rennes University Hospital; University Hospital, Essen; Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron; The Netherlands Cancer Institute; Servicio Madrileño de Salud, Madrid, Spain; Hospital Universitario 12 de Octubre; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano; Medical University of Vienna; FAKULTNI NEMOCNICE OLOMOUC; International Kidney Cancer Coalition; Association pour la Recherche sur les Tumeurs du Rein; Resilience; PRIMAA; Queen Mary University of London
First posted
Apr 15, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Systemic therapy for renal cell carcinoma (RCC) relies on 2 classes of agents: anti-angiogenic targeted therapy (Vascular endothelial growth factor Tyrosine Kinase Inhibitor- VEGFR TKI) and immune checkpoint inhibitor (ICI), targeting either PD1/PDL1 axis or CTLA4. Combination therapy is SOC for clear cell RCC in all guidelines with either ICI-ICI or ICI-VEGFR TKI. However, no head-to-head comparison have been performed between the 2 approaches and patients are treated based on physician decision without clinical /biomarker factors to guide treatment selection. PDL1 staining is, to date, the biomarker that has demonstrated its ability to enrich for overall survival benefit favoring ICI-ICI strategy in PDL1(+) and ICI-VEGFR TKI in PDL1(-) patients. Study design has been developed to demonstrate that ICI-ICI is superior to ICI-VEGFR TKI in prolonging Overall Survival (OS) for PDL1(+) patients and to demonstrate that ICI-VEGFR TKI is superior to ICI-ICI in prolonging Progression Free Survival (PFS) and OS for PDL1(-) patients.

Conditions

  • Metastatic Kidney Cancer
  • Metastatic Kidney Carcinoma

Interventions

  • NivolumabDrug

    Briefly, nivolumab is administered as an approximately 30-minute (240mg every 2 weeks) or 60-minute (480mg every 4 weeks) IV infusion. Nivolumab is to be administered first. The nivolumab infusion must be promptly followed by a saline flush to clear the line of nivolumab before starting the ipilimumab infusion.

  • IpilimumabDrug

    The second infusion will always be ipilimumab and will start at least 30 minutes after completion of the nivolumab infusion. Ipilimumab is to be administered as an approximately 30-minute IV infusion. When administered together, nivolumab and ipilimumab will be administered on Day 1 of each 21-day cycle.

  • PembrolizumabDrug

    Pembrolizumab is to be administered as an approximately 30-minute IV infusion.

  • CabozantinibDrug

    Cabozantinib is a medication that is taken orally every day, once a day away from meals at the initial dose of 40 mg/day.

  • AxitinibDrug

    Axitinib is a medication that is taken orally every day, 2 times a day continuously, at the starting dose of 5mg x2/day.

  • LenvatinibDrug

    Lenvatinib is a medication that is taken orally every day, once a day at the initial dose of 20mg/day.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS).Time frame: At end of study, 97 months

Locations

46 sites in 4 countries. Site status is shown where the registry gives one.

  • Medical University of Vienna

    Vienna, Austria · Not yet recruiting

  • Masarykův onkologický ústav, Masaryk Memorial Cancer Institute (MOU)

    Brno, Czechia · Not yet recruiting

  • Fakultní nemocnice Hradec Králová, University Hospital Hradec Kralove (FNHK)

    Hradec Králové, Czechia · Not yet recruiting

  • Fakultní nemocnice Olomouc, University Hospital Olomouc (FNOL)

    Olomouc, Czechia · Recruiting

  • Fakultní nemocnice v Motole, University Hospital Motol (MOTOL)

    Prague, Czechia · Not yet recruiting

  • Institut de Cancérologie de l'Ouest - Angers

    Angers, France · Recruiting

  • CHU Angers

    Angers, France · Recruiting

  • Institut Sainte Catherine

    Avignon, France · Recruiting

  • CH de la Côte Basque

    Bayonne, France · Recruiting

  • Hôpital Jean Minjoz

    Besançon, France · Recruiting

  • CHU de Bordeaux Hôpital Saint-André

    Bordeaux, France · Not yet recruiting

  • Centre François Baclesse

    Caen, France · Recruiting

  • CH Châlon Sur Saône

    Chalon-sur-Saône, France · Not yet recruiting

  • Centre Jean Perrin

    Clermont-Ferrand, France · Not yet recruiting

  • Hôpital Henri Mondor

    Créteil, France · Recruiting

  • Centre Georges-François Leclerc

    Dijon, France · Recruiting

  • CHU Grenoble

    Grenoble, France · Recruiting

  • CHD Vendée

    La Roche-sur-Yon, France · Recruiting

  • Centre Oscar Lambret

    Lille, France · Not yet recruiting

  • Polyclinique de Limoges

    Limoges, France · Recruiting

  • Centre Léon Bérard

    Lyon, France · Not yet recruiting

  • Institut Paoli-Calmettes

    Marseille, France · Recruiting

  • Institut Régional du Cancer de Montpellier

    Montpellier, France · Recruiting

  • Centre Antoine Lacassagne

    Nice, France · Recruiting

  • CHU de Nîmes

    Nîmes, France · Recruiting

  • Hôpital de la Pitié Salpêtrière

    Paris, France · Not yet recruiting

  • Hôpital Bichat - Claude Bernard

    Paris, France · Not yet recruiting

  • Hôpital Tenon

    Paris, France · Recruiting

  • Hôpital Saint-Louis

    Paris, France · Recruiting

  • Institut Mutualiste Montsouris

    Paris, France · Recruiting

  • CH de Pau

    Pau, France · Recruiting

  • Hospices Civils de Lyon

    Pierre-Bénite, France · Recruiting

  • CHU Poitiers

    Poitiers, France · Recruiting

  • Institut Godinot

    Reims, France · Recruiting

  • Centre Eugène Marquis

    Rennes, France · Recruiting

  • CHU Saint-Etienne

    Saint-Etienne, France · Not yet recruiting

  • Institut de Cancérologie de l'Ouest - Saint Herblain

    Saint-Herblain, France · Recruiting

  • HIA Bégin

    Saint-Mandé, France · Recruiting

  • CHU Sud Réunion

    Saint-Pierre, France · Recruiting

  • Institut de cancérologie Strasbourg Europe

    Strasbourg, France · Recruiting

Showing 40 of 46 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.